Myriad Genetics (MYGN) Non-Current Assets (2010 - 2026)

Myriad Genetics has disclosed Non-Current Assets across 17 years of filings, most recently posting $360.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 49.8% year-over-year to $360.9 million; the TTM figure through Mar 2026 stood at $1.5 billion (down 50.13% YoY), while the FY2025 annual figure was $374.0 million, down 48.74% from the prior year.
• Non-Current Assets eased to $360.9 million in Q1 2026, from $374.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for MYGN reached as high as $924.1 million in Q4 2022 and fell as low as $360.9 million in Q1 2026.
• The 5-year median for Non-Current Assets is $820.2 million (2024), against an average of $725.5 million.
• Annual changes were most pronounced in 2022 — Non-Current Assets rose 10.55% — and 2025, when it tumbled 51.36%.
• A 5-year view of Non-Current Assets shows it stood at $924.1 million in 2022, then retreated by 9.87% to $832.9 million in 2023, then fell by 12.4% to $729.6 million in 2024, then sank by 48.74% to $374.0 million in 2025, then decreased by 3.5% to $360.9 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $360.9 million, $374.0 million, and $383.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.